APC Anti-p53 antibody [Y5],Abcam,AB310851

What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

IHC-P, Antibody Labelling, Target Binding Affinity, Flow Cyt (Intra), ICC/IF

Conjugate

APC

Platform ID

BAB523049489

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAPC Anti-p53 antibody [Y5]
Cat. No.AB310851
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationAPC
ApplicationIHC-P, Antibody Labelling, Target Binding Affinity, Flow Cyt (Intra), ICC/IF
ClonalityMonoclonal
Clone NumberY5
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed : 11025664, PubMed : 12524540, PubMed : 12810724, PubMed : 15186775, PubMed : 15340061, PubMed : 17317671, PubMed : 17349958, PubMed : 19556538, PubMed : 20673990, PubMed : 20959462, PubMed : 22726440, PubMed : 24051492, PubMed : 24652652, PubMed : 35618207, PubMed : 36634798, PubMed : 38653238, PubMed : 9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed : 11025664, PubMed : 12524540, PubMed : 12810724, PubMed : 15186775, PubMed : 15340061, PubMed : 17189187, PubMed : 17317671, PubMed : 17349958, PubMed : 19556538, PubMed : 20673990, PubMed : 20959462, PubMed : 22726440, PubMed : 24051492, PubMed : 24652652, PubMed : 38653238, PubMed : 9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed : 11025664, PubMed : 12524540, PubMed : 12810724, PubMed : 15186775, PubMed : 15340061, PubMed : 17317671, PubMed : 17349958, PubMed : 19556538, PubMed : 20673990, PubMed : 20959462, PubMed : 22726440, PubMed : 24051492, PubMed : 24652652, PubMed : 9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed : 12524540, PubMed : 17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed : 12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed : 12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed : 24051492). See full target information TP53

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.